top of page
Comparative analysis of manufacturing hurdles in vaccine and gene therapy development
Post-Covid era brought with it a renewed interest and investment in biotechnology development, more specifically in vaccines and cell & gene therapy. This assessment explores the manufacturing and regulatory challenges for conventional vaccines, mRNA vaccines, and cell gene therapies. Comparative analysis was performed between conventional and mRNA vaccines, outlined cell & gene therapy challenges, and a final comparison between regulatory challenges in vaccine vs cell & gene therapy production. This review seeks to provide prospective biotechnology professionals with insights on problem areas in development and manufacturing structure for biologics.
bottom of page